儿童癫痫基因组检测结果重新解读的临床价值
本研究回顾性重新解读了309例儿科患者的癫痫基因组检测结果,平均年龄5.6岁。185例报告了基因变异,其中36.2%的变异分类发生变化,31.3%的患者诊断改变;研究建议至少每2年重新解读一次基因组检测结果。
要点
- 185例报告变异的患儿中,36.2%的变异分类在重新解读后发生改变。
- 67例变异分类改变者中,21例(31.3%)的诊断发生改变。
- 研究提示基因组检测结果应至少每2年重新解读一次。
核心结论
- 重新解读既往报告的基因组检测结果可导致较高的变异分类和诊断改变率。
- 建议基因组检测结果应至少每2年重新解读一次。
研究设计与样本
- 回顾性研究,纳入2012年7月1日至2015年8月31日在单一三级儿科医疗中心接受癫痫基因组检测的309例儿科患者,2017年5月采用2015年共识标准重新解读所有报告变异。
主要发现
- 309例患者中185例报告了基因变异,其中61例有遗传诊断,124例仅报告VUS。
- 重新解读后,185例中67例(36.2%)的变异分类改变,67例中21例(31.3%)诊断改变。
- 61例有遗传诊断者中19例(31.1%)结果被重新分类,124例未确诊者(仅VUS)中48例(38.7%)结果被重新分类。
- 研究最后2年发布的报告中,16例有致病或可能致病变异者中4例(25.0%)被重新分类,41例有VUS者中11例(26.8%)被重新分类。
关键数值与推荐
- 重新解读采用2015年遗传性基因变异解读共识标准和指南,分类为致病或可能致病变异、意义不明确变异(VUS)、良性或可能良性变异三个层级。
临床怎么用
- 对儿科癫痫患者的基因组检测结果应定期重新解读,建议至少每2年一次,以更新变异分类和诊断。
局限性
- 本研究为单中心回顾性研究,重新解读仅采用2015年共识标准,未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Clinical genomic tests that examine the DNA sequence of large numbers of genes are commonly used in the diagnosis and management of epilepsy in pediatric patients. The permanence of genomic test result interpretations is not known. OBJECTIVE: To investigate the value of reinterpreting previously reported genomic test results. DESIGN, SETTING, AND PARTICIPANTS: This study retrospectively reviewed and reinterpreted genomic test results from July 1, 2012, to August 31, 2015, for pediatric patients who previously underwent genomic epilepsy testing at a single tertiary care pediatric health care facility. Reinterpretation of previously reported variants was conducted in May 2017. MAIN OUTCOMES AND MEASURES: Patient reports from clinical genomic epilepsy tests were reviewed, and all reported genetic variants were reinterpreted using 2015 consensus standards and guidelines for interpreting hereditary genetic variants. Three classification tiers were used in the reinterpretation: pathogenic or likely pathogenic variant, variant of uncertain significance (VUS), or benign or likely benign variant. RESULTS: A total of 309 patients had genomic epilepsy tests performed (mean [SD] age, 5.6 [0.8] years; 163 [52.8%] male), and 185 patients had a genetic variant reported. The reported variants resulted in 61 patients with and 124 patients without a genetic diagnosis (VUS variants only). On reinterpretation of all reported variants, 67 of the 185 patients (36.2%) had a change in variant classification. Of the 67 patients with a genetic variant change in interpretation, 21 (31.3%) experienced a change in diagnosis. During the 5 years of the study, 19 of 61 patients (31.1%) with a genetic diagnosis and 48 of 124 patients (38.7%) with undiagnosed conditions (VUS only) had their results reclassified. Review of genomic reports issued during the final 2 years of the study identified reclassification of variants in 4 of 16 patients (25.0%) with a pathogenic or likely pathogenic variant and 11 of 41 patients (26.8%) with a VUS. CONCLUSIONS AND RELEVANCE: The identified high rate of reinterpretation in this study suggests that interpretation of genomic test results has rapidly evolved during the past 5 years. These findings suggest that reinterpretation of genomic test results should be performed at least every 2 years.
引用
- SoRelle JA, Thodeson DM, Arnold S, et al. Clinical Utility of Reinterpreting Previously Reported Genomic Epilepsy Test Results for Pediatric Patients. JAMA Pediatr. 2019. PMID: 30398534. doi:10.1001/jamapediatrics.2018.2302
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。